Mechanisms of EXO1 regulation in response to radiation-induced DNA damage
Mechanisms of EXO1 regulation in response to radiation-induced DNA damage
批准号:
9926813
负责人:
Sandeep Burma
金额:
$30.49万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-11-28 至 2022-04-30
关键词:
BackBindingCell CycleCell SurvivalCellsClinical TrialsComplexDNADNA DamageDNA Double Strand BreakDNA RepairDouble Strand Break RepairEXO1 geneEnzymesEventExcisionExerciseG2 PhaseGenomic InstabilityGenomicsGoalsHumanIn VitroIonizing radiationLesionMaintenanceMalignant - descriptorMalignant NeoplasmsModificationMolecularNonhomologous DNA End JoiningPathway interactionsPhasePhosphorylationPlayPost-Translational Protein ProcessingProcessProteinsPublishingRadiationRadiation Induced DNA DamageRadiation therapyRadiosensitizationRegimenRegulationResearchResistanceRoleS PhaseSiteTestingTherapeuticUbiquitinUbiquitinationWorkbasecancer cellcancer therapyexperimental studygenome integrityhomologous recombinationin vivoinhibitor/antagonistnovelpreservationpreventpublic health relevanceradiation responserecruitrepairedresponsespleen exonuclease
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Ionizing radiation (IR) remains one of the mainstays of cancer therapy. The most deleterious lesion induced by IR is the DNA double-strand break (DSB). Accurate repair of DSBs is essential for preventing loss of genomic integrity and malignant transformation. Efficient repair of DSBs also underlies the resistance of many cancers to radiation therapy. A cell must choose between two major repair pathways to fix these breaks - non- homologous end joining (NHEJ), an error-prone pathway that is operative in all phases of the cell cycle or homologous recombination (HR), an error-free pathway that is restricted to the post-replicative phases of the cell cycle. Optimal usage of these two pathways is vital for the maintenance of genomic integrity and cell survival in the face of genomic insults. The DNA end resection step of HR is a pivotal point at which correct repair pathway choice is exercised. Importantly, research from our lab and others has established that the 5' to 3' exonuclease EXO1 is a critical player in DNA end resection and repair pathway choice in human cells. While DNA end resection is currently an avidly researched topic in the field of DNA repair, the exact sequence of molecular events involving EXO1 that allows commitment to a particular repair pathway is not well worked out. Exciting new results from our lab demonstrate that EXO1 is phosphorylated by CDKs 1/2 in a cell cycle- dependent manner and by ATM/ATR in a DNA damage-dependent manner to promote DNA end resection. However, soon after DNA damage, EXO1 is SUMOylated, ubiquitinated, and rapidly targeted for degradation, presumably to prevent uncontrolled resection of DNA ends. It is important to mechanistically understand how these and other post translational modifications stimulate or restrain EXO1's functions in the cellular response to IR. Towards this goal, we propose to develop a comprehensive picture of cell cycle- and IR-dependent modifications and interacting partners of EXO1, and to mechanistically understand how these modifications promote EXO1 activation and subsequent degradation in response to IR. Based upon our preliminary results, we hypothesize that EXO1 activation and inactivation is a tightly controlled process involving phosphorylation, SUMOylation and ubiquitination events that fine-tune DNA end resection, optimize DSB repair, and preserve genomic integrity. Understanding the sequence and functions of EXO1 post- translational modifications and the exact choreography of EXO1 and its interacting partners at DSBs will be of paramount importance in developing more effective radiosensitization approaches that target the critical DNA end resection step. Specifically, we propose to: 1) Test the hypothesis that phosphorylation of EXO1 by CDKs and PI3KKs regulates DNA end resection and influences repair pathway choice, 2) Test the hypothesis that EXO1 degradation post-radiation restrains DNA end resection and preserves genomic integrity, and 3) Test the hypothesis that blocking EXO1 activation with CDK 1/2 inhibitors may be a viable strategy for therapeutically sensitizing cancers to ionizing radiation.
期刊论文(11)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1038/nn.4584
发表时间:
2017-08
期刊:
Nature neuroscience
影响因子:
25
作者:
[Guo G, Gong K, Ali S, Ali N, Shallwani S, Hatanpaa KJ, Pan E, Mickey B, Burma S, Wang DH, Kesari S, Sarkaria JN, Zhao D, Habib AA]
通讯作者:
Habib AA
DOI:
10.21037/atm.2017.01.67
发表时间:
2017-02
期刊:
Annals of translational medicine
影响因子:
--
作者:
[P. Todorova;B. Mukherjee;S. Burma]
通讯作者:
P. Todorova;B. Mukherjee;S. Burma
DOI:
10.1093/narcan/zcac044
发表时间:
2023-03
期刊:
NAR cancer
影响因子:
5.1
作者:
[]
通讯作者:
DOI:
10.1074/jbc.m116.758235
发表时间:
2017-02-17
期刊:
The Journal of biological chemistry
影响因子:
--
作者:
[Kim HS, Nickoloff JA, Wu Y, Williamson EA, Sidhu GS, Reinert BL, Jaiswal AS, Srinivasan G, Patel B, Kong K, Burma S, Lee SH, Hromas RA]
通讯作者:
Hromas RA
DOI:
10.1002/1878-0261.12040
发表时间:
2017-05
期刊:
Molecular oncology
影响因子:
6.6
作者:
[Kalimutho M, Bain AL, Mukherjee B, Nag P, Nanayakkara DM, Harten SK, Harris JL, Subramanian GN, Sinha D, Shirasawa S, Srihari S, Burma S, Khanna KK]
通讯作者:
Khanna KK
共 7 条
Enhancing MAPK-targeted Therapy in PDX Models of BRAF-Mutant Pediatric Brain Tumors
-
批准号:10175336
-
项目类别:
-
资助金额:$55.41万
-
财政年份:2021
-
负责人:Sandeep Burma
-
依托单位:
Enhancing MAPK-targeted Therapy in PDX Models of BRAF-Mutant Pediatric Brain Tumors
-
批准号:10368111
-
项目类别:
-
资助金额:$54.48万
-
财政年份:2021
-
负责人:Sandeep Burma
-
依托单位:
Radiation-induced senescence in the brain microenvironment: Implications for glioblastoma recurrence and therapy
-
批准号:10394384
-
项目类别:
-
资助金额:$34.94万
-
财政年份:2021
-
负责人:Sandeep Burma
-
依托单位:
Radiation-induced senescence in the brain microenvironment: Implications for glioblastoma recurrence and therapy
-
批准号:10211559
-
项目类别:
-
资助金额:$36.81万
-
财政年份:2021
-
负责人:Sandeep Burma
-
依托单位:
Enhancing MAPK-targeted Therapy in PDX Models of BRAF-Mutant Pediatric Brain Tumors
-
批准号:10553688
-
项目类别:
-
资助金额:$55.31万
-
财政年份:2021
-
负责人:Sandeep Burma
-
依托单位:
Radiation-induced senescence in the brain microenvironment: Implications for glioblastoma recurrence and therapy
-
批准号:10578763
-
项目类别:
-
资助金额:$34.95万
-
财政年份:2021
-
负责人:Sandeep Burma
-
依托单位:
Mechanisms of EXO1 regulation in response to radiation-induced DNA damage
-
批准号:10063785
-
项目类别:
-
资助金额:$19.37万
-
财政年份:2019
-
负责人:Sandeep Burma
-
依托单位:
Augmented homologous recombination as a mechanism of acquired temozolomide resistance in glioblastoma
-
批准号:9325481
-
项目类别:
-
资助金额:$21.14万
-
财政年份:2016
-
负责人:Sandeep Burma
-
依托单位:
Molecular mechanisms of GBM radioresistance and strategies for radiosensitization
-
批准号:8605809
-
项目类别:
-
资助金额:$32.0万
-
财政年份:2011
-
负责人:Sandeep Burma
-
依托单位:
Molecular mechanisms of GBM radioresistance and strategies for radiosensitization
-
批准号:8042256
-
项目类别:
-
资助金额:$32.89万
-
财政年份:2011
-
负责人:Sandeep Burma
-
依托单位:
Molecular mechanisms of GBM radioresistance and strategies for radiosensitization
-
批准号:8206502
-
项目类别:
-
资助金额:$32.92万
-
财政年份:2011
-
负责人:Sandeep Burma
-
依托单位:
Molecular mechanisms of GBM radioresistance and strategies for radiosensitization
-
批准号:8403553
-
项目类别:
-
资助金额:$31.01万
-
财政年份:2011
-
负责人:Sandeep Burma
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: